UNSPSC 51144110: Amphetamine sulfate

This classification denotes a cns stimulant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DPV8NK46S. European Medicines Agency schedules Amfetamine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00438MIG. Amphetamine sulfate generally arises in the molecular formula 2C9H13N.H2O4S. The term 'amphetamine sulfate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule amphetamine sulfate under HS 29214600.

As of Q4 2014, AMPHETAMINE SULFATE remains US FDA's Preferred Term for this commodity. Amphetamine sulfate bears US NLM identifiers UMLS ID C0282051 and NCI Concept Code C28822. SMILES: CC(CC1CCCCC1)N.CC(CC1CCCCC1)N.OS(=O)(=O)O.

UNSPSC 51144110 Amphetamine sulfate is a Commodity code that in state and local procurement practice covers controlled pharmaceutical substances and their procurement through health agencies and cooperative purchasing consortia rather than amphetamine sulfate specifically — the recent opportunities tagged to this code show state and local governments buying naloxone and harm-reduction products, multi-source generic pharmaceuticals, and exploring direct-to-manufacturer prescription programs through pharmacy benefit initiatives. State and local issuing bodies soliciting under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida is a repeat buyer in the recent record, procuring naloxone and drug deactivation systems annually through competitive bidding to support community health initiatives with quarterly deliveries. The scope spans emergency overdose-reversal products, generic pharmaceuticals supplied through authorized wholesalers, and exploratory procurement for direct contracting arrangements between state agencies and manufacturers.

Recent activity concentrates in Florida and Texas, with participation from the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving multiple states including Oregon. Representative opportunities include Seminole County's IFB60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually, posted June 30, 2026, with response due July 26, 2023 (noting the date anomaly in the source); the Texas Health and Human Services Commission's RFI HHS0017013 posted April 3, 2026 to assess vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026 with proposals due March 26, 2026. The MMCAP procurement requires vendors to maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), certify cGMP and Drug Supply Chain Security Act compliance, and accept a 3 percent administrative fee on all contract purchases.